Compare Tempus AI (TEM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs State Street SPDR S&P Biotech ETF — how do they compare? Tempus AI trades at $70.06 (market cap $12.58B), while State Street SPDR S&P Biotech ETF trades at $153.56 (market cap $10.11B). The key difference: Tempus AI is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 22 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TEM | XBI | |
|---|---|---|
Market Cap | $12.58B | $10.11B |
Volume | 7,444,569 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $99.28 | $169.55 |
52-Week Low | $41.55 | $104.99 |
Typical Hold Time | 22 Days | 37 Days |
Enterprise Value | $13.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $72.15, up 2.65% today, with a bullish technical signal and strong analyst support. The stock shows recent earnings beats but remains unprofitable, with a net income margin of -17.77% for 2026. Positive developments include FDA clearance for an AI product and expanded data partnerships, fueling investor optimism in the healthtech sector.
Outlook is cautiously optimistic given growth potential in AI-driven diagnostics, but high valuation (P/S 8.61) and persistent losses pose risks. Upside hinges on revenue scaling and path to profitability, with a consensus price target of $72.60 suggesting limited near-term gains from current levels.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
